| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-12-07 | Bluebird bio (USA - MA) TC BioPharm (UK) | gamma delta CAR T cells | hematological cancers, solid tumors | research - development - R&D | Cancer - Oncology | Development agreement |
| 2017-12-06 | Servier (France) Vernalis (UK) | drugs for a new undisclosed target | R&D - research | Cancer - Oncology | Milestone | |
| 2017-12-06 | Nosopharm (France) | member of the supervisory board | nomination | Infectious diseases | Nomination | |
| 2017-12-06 | Juno Therapeutics (USA - WA) Fred Hutchinson Cancer Research Center (USA - WA) OncoTracker (USA - CA) | combinations of gamma secretase inhibitors (GSIs) and BCMA-directed engineered T cells | multiple myeloma | licensing | Cancer - Oncology | Licensing agreement |
| 2017-12-06 | Tapimmune (USA - FL) | chief medical officer | nomination | Cancer - Oncology | Nomination | |
| 2017-12-06 | BioInvent (Sweden) Transgene (France) | oncolytic virus candidates encoding an anti-CTLA-4 antibody sequence | development | Cancer - Oncology | Development agreement | |
| 2017-12-05 | Crossbeta Biosciences (The Netherlands) Probiodrug (Germany) | biomarkers | Alzheimer's disease | collaboration | Neurodegenerative diseases | Collaboration agreement |
| 2017-12-05 | Juno Therapeutics (USA - WA) Eli Lilly (USA - IN) | LY3039478 | multiple myeloma | licensing | Cancer - Oncology | Licensing agreement |
| 2017-12-05 | Shire (UK - USA) Rani Therapeutics (USA - CA) | Rani Pill™ technology for the oral delivery of factor VIII (FVIII) therapy | hemophilia A | research - licensing | Rare diseases - Genetic diseases - Hematological diseases | Research agreement |
| 2017-12-04 | Cellectis (France) | vice-president | nomination | Cancer - Oncology - Rare diseases | Nomination | |
| 2017-12-04 | Cellectis (France) | vice-president - chief medical officer | nomination | Cancer - Oncology - Rare diseases | Nomination | |
| 2017-12-04 | Idorsia (Switzerland) Janssen Biotech, a J&J company (USA - NJ) | aprocitentan (ACT-132577) | development - commercialisation | Collaboration agreement | ||
| 2017-12-01 | Shire (UK - USA) | chief scientific officer, chief medical officer | nomination | Nomination | ||
| 2017-11-30 | Orchard Therapeutics (UK) | new facility in the San Francisco Bay Area | opening of new premises | Rare diseases - Genetic diseases | Opening of new premises | |
| 2017-11-29 | Illumina (USA - CA) | Solutions Center on the Genopole Campus in Évry | establishment of a new subsidiary in the EU | Technology - Services | Establishment of a new subsidiary in the EU | |
| 2017-11-29 | Bluebird bio (USA - MA) | manufacturing facility in Durham | plant acquisition | Plant acquisition | ||
| 2017-11-28 | Synpromics (UK) UCL (UK) | synthetic gene promoters | Parkinson's disease | research - development - R&D | Neurodegenerative diseases | Development agreement |
| 2017-11-27 | Philips (The Netherlands) Stratasys (USA - MN) 3D Systems (USA - IL) | advanced 3D modeling applications for radiologists | collaboration | Technology - Services | Collaboration agreement | |
| 2017-11-27 | Biomarin Pharmaceutical (USA - CA) undisclosed | Rare Pediatric Disease Priority Review Voucher (PRV) | commercialisation | Rare diseases | Commercialisation agreement | |
| 2017-11-27 | Orchard Therapeutics (UK) the University of Manchester (UK) | lentivirus-based autologous ex-vivo gene therapy | mucopolysaccharidosis type IIIA (Sanfilippo B syndrome) | licensing | Rare diseases - Genetic diseases | Licensing agreement |
